Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares Bought by GSA Capital Partners LLP

GSA Capital Partners LLP lifted its position in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 283.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 67,746 shares of the biopharmaceutical company's stock after purchasing an additional 50,072 shares during the period. GSA Capital Partners LLP owned about 0.11% of Sage Therapeutics worth $539,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. ProShare Advisors LLC lifted its position in shares of Sage Therapeutics by 31.2% during the 4th quarter. ProShare Advisors LLC now owns 18,281 shares of the biopharmaceutical company's stock worth $99,000 after purchasing an additional 4,350 shares during the last quarter. Invesco Ltd. lifted its position in shares of Sage Therapeutics by 5.3% during the 4th quarter. Invesco Ltd. now owns 92,528 shares of the biopharmaceutical company's stock worth $502,000 after purchasing an additional 4,629 shares during the last quarter. BNP Paribas Financial Markets lifted its position in shares of Sage Therapeutics by 9.3% during the 4th quarter. BNP Paribas Financial Markets now owns 77,560 shares of the biopharmaceutical company's stock worth $421,000 after purchasing an additional 6,574 shares during the last quarter. Wells Fargo & Company MN lifted its position in Sage Therapeutics by 27.3% in the fourth quarter. Wells Fargo & Company MN now owns 33,051 shares of the biopharmaceutical company's stock valued at $179,000 after acquiring an additional 7,087 shares during the last quarter. Finally, Voya Investment Management LLC lifted its position in Sage Therapeutics by 21.1% in the fourth quarter. Voya Investment Management LLC now owns 41,955 shares of the biopharmaceutical company's stock valued at $228,000 after acquiring an additional 7,319 shares during the last quarter. 99.22% of the stock is owned by hedge funds and other institutional investors.

Sage Therapeutics Stock Performance

NASDAQ SAGE remained flat at $8.68 during trading hours on Friday. The company has a market capitalization of $543.54 million, a P/E ratio of -1.78 and a beta of 0.26. Sage Therapeutics, Inc. has a 1 year low of $4.62 and a 1 year high of $11.44. The company has a 50 day moving average price of $8.51 and a 200-day moving average price of $7.71.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The biopharmaceutical company reported ($0.79) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.96) by $0.17. The firm had revenue of $31.66 million during the quarter, compared to analysts' expectations of $16.69 million. Sage Therapeutics had a negative net margin of 427.78% and a negative return on equity of 67.10%. The firm's revenue for the quarter was up 266.0% on a year-over-year basis. During the same period in the prior year, the company posted ($1.70) earnings per share. Equities research analysts expect that Sage Therapeutics, Inc. will post -3.52 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on SAGE shares. Needham & Company LLC reissued a "hold" rating on shares of Sage Therapeutics in a research report on Monday, June 16th. Truist Financial set a $9.00 price target on shares of Sage Therapeutics and gave the company a "hold" rating in a research report on Tuesday, June 17th. Robert W. Baird boosted their price target on shares of Sage Therapeutics from $7.00 to $9.00 and gave the company a "neutral" rating in a research report on Friday, June 20th. Canaccord Genuity Group upped their target price on shares of Sage Therapeutics from $8.00 to $8.50 and gave the company a "hold" rating in a report on Tuesday, June 17th. Finally, Piper Sandler cut shares of Sage Therapeutics from a "strong-buy" rating to a "hold" rating and reduced their target price for the company from $9.00 to $8.50 in a report on Tuesday, June 17th. One equities research analyst has rated the stock with a sell rating and fourteen have issued a hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $7.85.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.